Body weight reduction by analog of prolactin-releasing peptide

Although incretin (GLP-1)-based drugs are highly successful for weight loss, there are some limitations to their use. 

Body weight in both rodents and humans is regulated by prolactin-releasing peptide and its cognate receptor, G protein-coupled receptor (GPR)10.

A modified prolactin-releasing peptide, NN501, with agonist properties at both GPR10 and neuropeptide FF receptor 2 (NPFFR2) causes significant weight loss without apparent side effects and with slower weight gain after cessation.

The authors also show that NN501 increases energy expenditure on treatment and has a sustained effect on fatty-acid oxidation, thus, potentially proving suitable as an alternative therapy for the treatment of obesity.

https://www.cell.com/cell-metabolism/fulltext/S1550-4131(25)00481-4

https://sciencemission.com/Analog-of-PLR--peptide-reduces-body-weight